Zimmer Biomet has announced plans to phase out its CPT Hip System by December due to a higher risk of postoperative fractures compared to similar devices. The FDA issued a warning based on research showing a 1.4% risk of thigh bone fractures with the CPT Hip System, higher than the 0.6%-1% rate for comparable implants. The company previously issued a recall in July to update instructions for use.
The global hip reconstruction devices market is projected to experience significant growth in the coming years, reaching US$ 6.7 billion by 2034. This expansion is fueled by the rising prevalence of hip-related conditions like osteoarthritis, an aging global population, and technological advancements in hip replacement procedures. The report delves into the market’s segmentation, key players, and regional insights.
